Top

International Journal of Clinical Oncology

Published in:

01-02-2020 | Metastasis | Original Article

FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis

Authors: Akira Watanabe, Norifumi Harimoto, Takehiko Yokobori, Kenichiro Araki, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Norihiro Ishii, Takahiro Yamanaka, Tadashi Handa, Tetsunari Oyama, Tetsuya Higuchi, Ken Shirabe

Published in: International Journal of Clinical Oncology | Issue 2/2020

Abstract

Background

Liver resection is the most effective procedure for colorectal cancer liver metastasis (CRLM); however, early recurrence is an important problem that affects the postoperative prognoses of patients with CRLM. We previously suggested a therapeutic algorithm for CRLM using fluorodeoxyglucose-positron emission tomography (FDG-PET) and revealed the applicability of FDG-PET in predicting the prognosis after liver resection of CRLM. In this study, we assessed the correlation between FDG-PET and biological viability such as proliferation or metabolic activity.

Methods

We retrospectively evaluated 61 patients who underwent hepatectomy for CRLM. We assessed hypoxia inducible factor-1α (HIF-1α), pyruvate kinase isozyme M2 (PKM2), glucose transporter 1 (GLUT1), and Ki-67 expression via immunohistochemistry and evaluated the correlation between standardized uptake value (SUV) and these factors.

Results

High HIF-1α, PKM2, and GLUT1 expression were positively correlated with high SUV expression (P = 0.0444, 0.0296, and 0.0245, respectively). Ki-67 and SUV were also positively correlated (P = 0.00164). HIF-1α expression and PKM2 expression were significantly correlated (P = 0.0430), and PKM2 expression and GLUT1 expression were extremely significantly correlated (P < 0.0001).

Conclusion

SUV reflected tumor proliferation or metabolic factors in CRLM. FDG-PET could be a useful modality for assessing tumor viability and may provide useful information regarding the appropriate treatment strategy for CRLM.

Available only for authorised users

Akgül Ö, Çetinkaya E, Ersöz Ş et al (2014) Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 20:6113–6122CrossRef

McNally SJ, Parks RW (2013) Surgery for colorectal liver metastases. Dig Surg 30:337–347CrossRef

Allard MA, Adam R, Giuliante F et al (2017) Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer 117:604–611CrossRef

Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999CrossRef

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 (discussion 318–321) CrossRef

Hadden WJ, de Reuver PR, Brown K et al (2016) Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford) 18:209–220CrossRef

Matias M, Casa-Nova M, Faria M et al (2015) Prognostic factors after liver resection for colorectal liver metastasis. Acta Med Port 28:357–369CrossRef

Beppu T, Sakamoto Y, Hasegawa K et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19:72–84CrossRef

Angelsen JH, Viste A, Loes IM et al (2015) Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World J Surg Oncol 13:328CrossRef

10.

Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 12:6305–6309CrossRef

11.

Wu Y, Li C, Zhao J et al (2016) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol 14:289CrossRef

12.

Willowson KP, Hayes AR, Chan DLH et al (2017) Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. EJNMMI Res 7:46CrossRef

13.

Watanabe A, Harimoto N, Araki K et al (2018) A new strategy based on fluorodeoxyglucose-positron emission tomography for managing liver metastasis from colorectal cancer. J Surg Oncol 118:1088–1095CrossRef

14.

Kato H, Kuwano H, Nakajima M et al (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921–928CrossRef

15.

Takahashi S, Kuroki Y, Nasu K et al (2006) Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res 26:4705–4711PubMed

16.

Moulton CA, Gu CS, Law CH et al (2014) Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 311:1863–1869CrossRef

17.

Muralidharan V, Kwok M, Lee ST et al (2012) Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med 53:1345–1351CrossRef

18.

Lee HS, Kim HO, Hong YS et al (2014) Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med 55:582–589CrossRef

19.

Riedl CC, Akhurst T, Larson S et al (2007) 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48:771–775CrossRef

20.

Binderup T, Knigge UP, Federspiel B et al (2013) Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics (Basel) 3:372–384CrossRef

21.

Sato J, Kitagawa Y, Yamazaki Y et al (2013) 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma. J Nucl Med 54:1060–1065CrossRef

22.

Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355CrossRef

23.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

24.

Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344CrossRef

25.

Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572CrossRef

26.

Hosseini-Nik H, Fischer SE, Moulton CA et al (2016) Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. Abdom Radiol (NY) 41:231–238CrossRef

27.

Meng X, Li H, Kong L et al (2016) MRI In rectal cancer: correlations between MRI features and molecular markers Ki-67, HIF-1alpha, and VEGF. J Magn Reson Imaging 44:594–600CrossRef

28.

Deng SM, Zhang W, Zhang B et al (2015) Correlation between the uptake of 18F-fluorodeoxyglucose (18F-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS One 10:e0129028CrossRef

29.

Shannon AM, Bouchier-Hayes DJ, Condron CM et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297–307CrossRef

30.

Bos R, van der Groep P, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581CrossRef

31.

Schindl M, Schoppmann SF, Samonigg H et al (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed

32.

Luo W, Hu H, Chang R et al (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145:732–744CrossRef

33.

Ouyang Y, Li H, Bu J et al (2016) Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis. Int J Biol Markers 31:e229–e234CrossRef

34.

Huang C, Huang Z, Bai P et al (2018) Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis. Onco Targets Ther 11:2075–2082CrossRef

35.

Yang Y, Wu K, Liu Y et al (2017) Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer: a meta-analysis. Medicine (Baltimore) 96:e8690CrossRef

36.

Masoud GN, Li W (2015) HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5:378–389CrossRef

37.

Yang W, Zheng Y, Xia Y et al (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14:1295–1304CrossRef

Title: FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis
Authors: Akira Watanabe
Norifumi Harimoto
Takehiko Yokobori
Kenichiro Araki
Norio Kubo
Takamichi Igarashi
Mariko Tsukagoshi
Norihiro Ishii
Takahiro Yamanaka
Tadashi Handa
Tetsunari Oyama
Tetsuya Higuchi
Ken Shirabe
Publication date: 01-02-2020
Publisher: Springer Singapore
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Clinical Oncology / Issue 2/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01557-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease

Leptomeningeal metastases arising from gynecological cancers

The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer

Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor

Clinicopathologic characteristics of malignant non-hematopoietic tumors first presented as an axillary mass with emphasis on occult breast carcinoma

Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck

Keynote webinar | Spotlight on antibody–drug conjugates in cancer